Abstract
Tumor necrosis, enhancement, and associated edema in patients with glioblastoma multiforme (GBM) represent biological variables that can be quantitated on preoperative MRI scans. We reviewed 48 highly selected patients, all of whom had supratentorial lesions, had undergone gross total tumor resection, and had received adjuvant treatments (radio- and chemotherapies). None of these patients had had surgery for recurrent tumor resection and none had harbored multifocal tumors. The median age was 50 years. The median Karnofsky performance score was 80. Multivariate analysis using the Cox regression model revealed that the strongest prognostic variable was the amount of tumor necrosis on preoperative scan (P < 0.001), with median survivals of 42, 24, 15, and 12 months for tumor necrosis grades of 0 (7 ‘pts’), I (11 ‘pts’),11 (9 ‘pts’), and III (21 ‘pts’), respectively. The intensity of enhancement of the tumor nodule was another prognostic factor (P = 0.003), with median survivals of 35, 18, and 13.5 months for enhancement grades of 0 (2 ‘pts’), I (22 ‘pts’), and II (24 ‘pts’), respectively. The extent of peritumoral edema had a quadratic effect (P = 0.001), with grades I (19 ‘pts’), II (22 ‘pts’), and III (7 ‘pts’) surviving for 24,12, and 20 months respectively. Location and volume of tumors were not statistically significant predictors of survival (P < 0.05). In conclusion, in this highly selected group, GBM patients with little or no necrosis and with less tumor nodule enhancement on preoperative MRI survive longer than patients with greater amounts of necrosis and greater degrees of tumor enhancement. In addition, a moderate degree of peritumoral edema is associated with worse prognosis.
Similar content being viewed by others
References
Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, Vangilder JC, Robertson JT, Ransohoff J, Mealey J, Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 71: 1–9, 1989.
Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hant WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma after surgery. New Engl J Med 303: 1323–1329, 1980.
Soffietti R, Chio A: Prognostic factors in cerebral astrocytic gliomas. In: Broggi C, Gerosa MA (eds) Cerebral Gliomas. Elsevier, Amsterdam, 1989, pp 149–150.
Glibert H, Kagan AR, Cassidy F, Wagner, Fuchs K, Fox D, Glibert D, Rao A, Nussbaum H, Forsythe A, Eder D, Latine, Youleless L, Chan P, Hintz BL: Glioblastoma multiforme is not a uniform disease. Cancer Clin Trials 4: 87–89, 1981.
Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 201–206, 1987.
Gehan EA, Walker MD: Prognostic factors for patients with brain tumors. Natl Cancer Inst Monograph 46: 189–195, 1977.
Scott GM, Gibberd FB: Epilepsy and other factors in the prognosis of gliomas. Acta Neurol Scandinav 61: 227–239, 1980.
Ammirati M, Galicich JH, Arbit E: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607–613, 1987.
Harch GR, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615–620, 1987.
Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56: 1106–1111, 1985.
Salcman M: Survival in glioblastoma: Historical perspective. Neurosurgery 7: 435–438, 1980.
Mahaley MS, Mettlin C, Natazajan N, Laws ER, Peace B: National survey of patterns of care for brain tumor patients. J Neurosurg 71: 826–836, 1989.
Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a prognostic criterion in malignant supratentorial astrocytric gliomas. Cancer 52: 550–554, 1983.
Forsting M, Albert FK, Sartor K: CT and MRI after brain tumor resection: How to obtain useful baseline scan. Tumor response monitoring and treatment planning. ART 91: 103, 1984.
Karnofsky DA, Barchend LJH, Armstead GC, Southam CM, Bernstein JL, Craer LF, Rhoads CP: Triethyline melanine in the treatment of neoplastic disease. Arch Intern Med 87: 477–516, 1951.
Bradley NJ, Bloom HJC, Davies AJS, Swift SM: Growth of human gliomas in immuno-deficient mice: A possible model for pre-clinical therapy. Br J Cancer 38: 263–272, 1978.
Bullard DE, Schold SC Jr, Bigner SH, Bigner DD: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40: 410–427, 1981.
Cox DR: Regression models and life tables. JR Stat Soc B34: 187–220, 1972.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Star Assoc 53: 457–481, 1958.
Pigott TJ: Clinical and cellular prognostic variables in glioblastoma multiforme. Diss Abstr Int B (abstract) 52 (5): 2495, 1991.
Michael MT, Beale SA: Magnetic resonance imaging of supratentorial neoplasms. In: Wilkins RH, Rengachary SS (eds) Neurosurgery Update I. McGraw-Hill Co., San Francisco, 1990, pp 12–28.
Alvord EC Jr: Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 51 (2): 127–132, 1992.
Segall HD, Destian S, Nelson MD Jr, Zee CS, Ahmadi J: CT and MR imaging in malignant gliomas. In: Apuzzo MLJ (ed) Malignant Cerebral Gliomas. AANS, Illinois, 1990, pp 63–77.
Front D, Israel O, Kohn S, Nit I: The blood tissue barrier of human brain tumors: Correlation of scintigraphic and ultrastructural findings-concise communication. J Nucl Med 25: 461–465, 1984.
Sage MR: Blood-brain barrier: Phenomenon of increasing importance to the imaging clinician. Am J Neuroradiol 138: 887–898, 1982.
Earnest FI, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS, Axley PL: Cerebral astrocytomas: Histopathological correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823–827, 1988.
Hirano A, Matsui T: Vascular structures in brain tumors. Hum Pathol 6: 611–621, 1975.
Long DM: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32: 127–144, 1970.
Caillé JM, Guibert-Tranier F, Calabet A, Billerey J, Piton J: Abnormal enhancements after contrast injection. In: Caillé JM, Salamon G (eds) Computerized Tomography. Berlin Springer, 1980, pp 166–171.
Bydder GM: Gd-DTPA finds its place in brain and cord imaging. Diagn Imaging 57: 212–217, 1988.
Chamberlin MC, Murovic JA, Levin VA: Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 38: 1371–1374, 1988.
Bydder GM, Steiner RE, Thomas DJ, Marshall J, Gildendale DJ, Young IR: Nuclear magnetic resonance imaging of the posterior fossa: 50 cases. Clin Radiol 34: 173–188, 1983.
Randell CP, Collins AG, Young IR: Nuclear magnetic resonance imaging of posterior fossa tumors. Am J Roentgenol 141: 489–496, 1986.
Levin VA, Hoffman WF, Heilbron DC, Norman D: Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg 52: 642–647, 1980.
Sawaya R: The fibrinolytic enzymes in the biology of brain tumors. In: Sawaya R (ed) Fibrinolysis and the Central Nervous System. Hanley and Belfus, Inc., Philadelphia, 1990, pp 106–126.
Sawaya R, Rämö J, Shi ML, Mandybur G: Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74: 480–486, 1991.
Felix R, Schörner W, Laniado M, Niendrof HP, Claussen C, Fiegler W, Speck U: Brain tumors: MR imaging with gadolinium-DTPA. Radiology 156: 681–688, 1985.
Wood JR, Green SB, Shapiro WR: The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6(2): 338–343, 1988.
Reeves GI, Marks JE: Prognostic significance of lesion size for glioblastoma multiforme. Radiology 132: 469–471, 1979.
Onoyama Y, Abe M, Yabumoto E, Sakamoto T, Nishidai T, Suyama S: Radiation therapy in the treatment of glioblastomas. Am J Roentgenol 126(3): 481–492, 1976.
Byar DP, Green SB, Strike TA: Prognostic factors for malignant glioma. In: Walker MD (ed) Oncology of the Nervous System. Martinus Nijhoff, Boston, 1983, pp 379–395.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hammoud, M.A., Sawaya, R., Shi, W. et al. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 27, 65–73 (1996). https://doi.org/10.1007/BF00146086
Issue Date:
DOI: https://doi.org/10.1007/BF00146086